We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

RTW Biotech Opportunities Ltd (RTW) ORD NPV

Sell:$1.31 Buy:$1.33 0 Change: $0.02 (1.54%)
Market closed Prices as at close on 28 March 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$1.31
Buy:$1.33
Change: $0.02 (1.54%)
Market closed Prices as at close on 28 March 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$1.31
Buy:$1.33
Change: $0.02 (1.54%)
Market closed Prices as at close on 28 March 2024 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.
Open:
$1.34
Trade high:
$1.34
Year high:
$1.43
Estimated NAV:
193.00
Previous close:
$1.30
Trade low:
$1.31
Year low:
$0.98
Premium/Discount:
-33.16%
Previous:
$0.01 (0.78%)
Previous:
$0.01
Volume:
476,288
Dividend yield:
n/a
Currency:
USD
Data delayed by at least 15 minutes.

Price

  • Net Asset Value (NAV)
RTW BIOTECH performance chart

Premium/Discount

RTW BIOTECH performance chart
Full interactive share price and premium / discount charts

Performance

Not available for this stock.

Trust Basics

Benchmark: Russell 2000 Biotech Growth
Annual management charge: n/a
Performance fee: Yes
Ongoing charge: 2.78%
Dividend yield: n/a
Dividend frequency: None
Total assets: £747m
Gross gearing: 0%
Market capitalisation:Market cap.: £500m
Shares in issue: 387.24 million
Legal structure Closed Ended Investment Company
Domicile: Guernsey
ISIN GG00BKTRRM22

Dividend information for this stock is not available.

Dividend information for this stock is not available.

Ready to invest?

Invest now

Want to invest?

To buy shares in , you'll need to have an account.

Explore the options

Important Documents



Objective

The Company seeks to achieve positive absolute performance and superior long-term capital appreciation, with a focus on forming, building, and supporting world-class life sciences, biopharmaceutical and medical technology companies. It intends to create a diversified portfolio of investments across a range of businesses, each pursuing the development of superior pharmacological or medical therapeutic assets to enhance the quality of life and/or extend patient life.

NET ASSET VALUE (NAV)

Estimated NAV: 193.00
Latest actual NAV: n/a
Latest actual NAV date: n/a
Premium/Discount: -33.16%
12m average Premium/Discount: -26.12%
NAV frequency: Monthly

Recent trade data is unavailable. We will be replacing it, however in the meantime the information is available on the London Stock Exchange website.

Security Weight
Rocket 10.31%
Ji Xing 7.75%
Equity Swaps 5.91%
Rtw Royalty Holdings 2 4.59%
Prometheus Biosciences 4.19%
Immunocore 3.81%
Avidity 3.22%
Beta Bionics 1.80%
Ni Kang 1.38%
Alcyone 1.28%

Top 10 sectors currently unavailable.

Country Weight
United States 5.05%
India 1.20%
Ireland 0.97%

Key Dates

Launch date: 29 October 2019
Financial year end: December
Next AGM: June 2024
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Prices provided by NBTrader. Charts provided by Factset. Dividend data provided by Digital Look. Recent trade data provided by MoneyAM. Trust basics, holding data, key dates, objective and NAV provided by Morningstar.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.